Sep. 18, 2009 (Business Wire) -- BioTime, Inc. (OTCBB:BTIM stock news) Chief
Executive Officer Michael West, Ph.D. will deliver the keynote
presentation on Tuesday, September 22, 2009 at the...
#20: BTIM Stock News, BioTime CEO Dr. Michael West to Present at World Stem Cells & Regenerative Medicine Congress 2009 and Discuss New Cell Lines with Cartilage-Forming Potential
BioTime, Inc. (OTCBB: BTIM stock news) Chief Executive Officer Michael West, Ph.D.
will deliver a presentation on May 14, 2009 at the World
Stem Cells and Regenerative Medicine...
#19: BTIM BioTime Launches New Stem Cell Lines in Anticipation of President Obama’s Removal of Restrictions on Federal Funding of Embryonic Stem Cell Research
New Cell Line Products to be Presented at Stem Cells World Conference
BioTime, Inc. (OTCBB:BTIM stock news) Chief Executive Officer Michael West, Ph.D.,
will deliver a...
#18: BTIM Stock: BioTime CEO Dr. Michael West Presents Keynote Address at Event Commemorating the 10th Anniversary of the First Derivation of Human Embryonic Stem Cells
BioTime, Inc. (OTCBB:BTIM stock) Chief Executive Officer Michael West, Ph.D.
will deliver a keynote presentation on Wednesday, November 19, at a
meeting in Madison, Wisconsin...
BioTime, Inc. (OTCBB:BTIM stock) and the International
Longevity Center-USA today announced a collaboration aimed at
research, education and advocacy for regenerative medicine and...
Embryonic Stem Cell Research Discussed in Biotechnology
``Visionaries'' Panel
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, PhD
today gave a...
BioTime Opens New GMP Laboratory for Production of Embryonic Stem Cell Technology Products
BioTime, Inc. (OTCBB:BTIM) announced today that it has opened an 11,000
square foot...
BioTime, Inc. (OTCBB:BTIM) announced its plan to build a relational database for its Embryome Sciences subsidiary that will display information useful in identifying the hundreds of cell types that...
BioTime, Inc. (OTCBB:BTIM) today announced that it has organized a new
subsidiary, Embryome Sciences, Inc. The mission of the new company is to
participate in the emerging field of...
EMERYVILLE, Calif.--(BUSINESS WIRE)--BioTime, Inc. (OTCBB:BTIM) announced today that a Phase II clinical
trial for Hextend® is being conducted in Japan
by Summit Pharmaceuticals...
EMERYVILLE, Calif.--(BUSINESS WIRE)--BioTime, Inc. (OTCBB:BTIM) today announced financial results for the
third quarter ended September 30, 2006. Revenues for the three months
ended...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Aug. 16, 2006--BioTime, Inc. (OTCBB:BTIM): -- Receives payment of $500,000 for China and Taiwan licenses -- 94% Increase in Royalties on Hextend Sales to be...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 22, 2005--BioTime, Inc. (OTCBB:BTIM) announced the completion of its subscription rights offer which expired at 5:00 p.m. New York time on December 21,...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 20, 2005--BioTime, Inc. (OTCBB:BTIM) announced today that it has entered into an addendum to its agreement with Summit Pharmaceuticals International...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 29, 2005--BioTime, Inc. (OTCBB:BTIM) today announced that it has amended the terms of its subscription rights offer by reducing the subscription price and...
